Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient

Jianxin Tao; Yunjuan Nie; Hui Wu; Liang Cheng; Yuanwang Qiu; Juanjuan Fu; Xiufeng Jiang

doi:10.3855/jidc.13081

Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient

Authors

Jianxin Tao Wuxi Clinical College, Nanjing Medical University, Wuxi, Jiangsu, China
Yunjuan Nie Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China
Hui Wu Department of Respiratory and Critical Care Medicine, Wuxi Fifth People's Hospital, Jiangnan University, Wuxi, Jiangsu, China
Liang Cheng Department of Respiratory and Critical Care Medicine, Wuxi Fifth People's Hospital, Jiangnan University, Wuxi, Jiangsu, China
Yuanwang Qiu Department of Respiratory and Critical Care Medicine, Wuxi Fifth People's Hospital, Jiangnan University, Wuxi, Jiangsu, China
Juanjuan Fu Department of Respiratory and Critical Care Medicine, Wuxi Fifth People's Hospital, Jiangnan University, Wuxi, Jiangsu, China
Xiufeng Jiang Wuxi Clinical College, Nanjing Medical University, Wuxi, Jiangsu, China

DOI:

https://doi.org/10.3855/jidc.13081

Keywords:

UCB-MSCs, COVID-19, ARDS, respiratory failure

Abstract

Introduction: The coronavirus disease 2019 (COVID-19) pandemic is spreading rapidly. Critically ill cases of COVID-19 can rapidly progress to acute respiratory distress syndrome and multiple organ failures. However, no effective drugs have been available till now, leading to more than 300,000 deaths up to 29 April 2020. Here, we present a critically ill case utilizing umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs).

Case presentation: A 72-year-old man was admitted, with the diagnosis of COVID-19, ARDS, type-2 diabetes, diabetic nephropathy, renal insufficiency, and hypertension. His clinical condition continually developed to be life-threatening even receiving various treatment options including antiviral therapy and extracorporeal membrane oxygenation. Between 28 February and 8 March 2020, the patient was given 5-time intravenous infusions of UCB-MSCs. His hematological and biochemical indexes, including lymphocytes and renal function improved. Pulmonary static compliance increased significantly and PaO₂/FiO₂ ratio maintained stable. On March 10, he received lung transplantation.

Conclusions: Our current findings suggested that UCB-MSCs therapy may show some positive effect in treating critical COVID-19 to some extent, for its delaying deterioration of the disease and efficacy in respiratory and renal function, though limited.

Downloads

Published

2020-10-31

How to Cite

Tao J, Nie Y, Wu H, Cheng L, Qiu Y, Fu J, Jiang X (2020) Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient. J Infect Dev Ctries 14:1138–1145. doi: 10.3855/jidc.13081

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 14 No. 10: October 2020

Section

Coronavirus Pandemic

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).